Status:

RECRUITING

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

Lead Sponsor:

Children's National Research Institute

Conditions:

Juvenile Idiopathic Arthritis

Systemic Lupus Erythematosus

Eligibility:

All Genders

5-21 years

Brief Summary

The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain ...

Eligibility Criteria

Inclusion

  • In order to be eligible for inclusion in the study, an individual must meet all of the following criteria:
  • Male or female ≥ 5 years of age at screening.
  • Documentation of a JIA, SLE or FM diagnosis as evidenced by history

Exclusion

  • Any individual who meets any of the following criteria will be excluded from participation in this study:
  • • Documented history of eye disease precluding pupillometry

Key Trial Info

Start Date :

July 16 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT04833465

Start Date

July 16 2021

End Date

December 1 2025

Last Update

July 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Children's National Health System

Washington D.C., District of Columbia, United States, 20010

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions | DecenTrialz